In the last trading session, 1.01 million Tango Therapeutics Inc (NASDAQ:TNGX) shares changed hands as the company’s beta touched 0.83. With the company’s per share price at $7.70 changed hands at $0.23 or 3.08% during last session, the market valuation stood at $824.98M. TNGX’s last price was a discount, traded about -69.22% off its 52-week high of $13.03. The share price had its 52-week low at $5.15, which suggests the last value was 33.12% up since then. When we look at Tango Therapeutics Inc’s average trading volume, we note the 10-day average is 1.19 million shares, with the 3-month average coming to 918.97K.

Analysts gave the Tango Therapeutics Inc (TNGX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.11. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TNGX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Tango Therapeutics Inc’s EPS for the current quarter is expected to be -0.37.

Tango Therapeutics Inc (NASDAQ:TNGX) trade information

Instantly TNGX was in green as seen at the end of in last trading. With action 0.13%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -22.22%, with the 5-day performance at 0.13% in the green. However, in the 30-day time frame, Tango Therapeutics Inc (NASDAQ:TNGX) is -30.76% down. Looking at the short shares, we see there were 10.45 million shares sold at short interest cover period of 11.32 days.

The consensus price target for the stock as assigned by Wall Street analysts is 13, meaning bulls need an upside of 40.77% from its current market value. According to analyst projections, TNGX’s forecast low is 13 with 18 as the target high. To hit the forecast high, the stock’s price needs a -133.77% plunge from its current level, while the stock would need to soar -68.83% for it to hit the projected low.

Tango Therapeutics Inc (TNGX) estimates and forecasts

Data shows that the Tango Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 0.79% over the past 6 months, a -17.59% in annual growth rate that is considerably lower than the industry average of 17.70%. Year-over-year growth is forecast to reach 15.80% up from the last financial year.

Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 7.81M. 10 analysts are of the opinion that Tango Therapeutics Inc’s revenue for the current quarter will be 8.17M. The company’s revenue for the corresponding quarters a year ago was 10.73M and 5.43M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -27.20%. The estimates for the next quarter sales put growth at 50.40%.

The 2024 estimates are for Tango Therapeutics Inc earnings to decrease by -22.90%.

TNGX Dividends

Tango Therapeutics Inc is expected to release its next quarterly earnings report in November.

Tango Therapeutics Inc (NASDAQ:TNGX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 12.93% of Tango Therapeutics Inc shares while 90.38% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 103.80%. There are 90.38% institutions holding the Tango Therapeutics Inc stock share, with TRV GP IV, LLC the top institutional holder. As of 2024-06-30, the company held 17.751% of the shares, roughly 19.2 million TNGX shares worth $164.75 million.

ECOR1 CAPITAL, LLC holds the second largest percentage of outstanding shares, with 12.3237% or 13.33 million shares worth $114.38 million as of 2024-06-30.